» Articles » PMID: 23403630

Expression Defect Size Among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2013 Feb 14
PMID 23403630
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Lynch syndrome is caused by a germline mutation in a mismatch repair gene, most commonly the MLH1 gene. However, one third of the identified alterations are missense variants with unclear clinical significance. The functionality of these variants can be tested in the laboratory, but the results cannot be used for clinical diagnosis. We therefore aimed to establish a laboratory test that can be applied clinically.

Experimental Design: We assessed the expression, stability, and mismatch repair activity of 38 MLH1 missense variants and determined the pathogenicity status of recurrent variants using clinical data.

Results: Four recurrent variants were classified as neutral (K618A, H718Y, E578G, V716M) and three as pathogenic (A681T, L622H, P654L). All seven variants were proficient in mismatch repair but showed defects in expression. Quantitative PCR, pulse-chase, and thermal stability experiments confirmed decreases in protein stability, which were stronger in the pathogenic variants. The minimal cellular MLH1 concentration for mismatch repair was determined, which corroborated that strongly destabilized variants can cause repair deficiency. Loss of MLH1 tumor immunostaining is consistently reported in carriers of the pathogenic variants, showing the impact of this protein instability on these tumors.

Conclusions: Expression defects are frequent among MLH1 missense variants, but only severe defects cause Lynch syndrome. The data obtained here enabled us to establish a threshold for distinguishing tolerable (clinically neutral) from pathogenic expression defects. This threshold allows the translation of laboratory results for uncertain MLH1 variants into pathogenicity statements for diagnosis, thereby improving the targeting of cancer prevention measures in affected families.

Citing Articles

Reclassification of Two MLH1 Variants of Uncertain Significance Utilizing Clinical and Functional Data.

Frederiksen J, Birkedal U, Bachmann S, Eliesen E, Rasmussen L, Pedersen K Mol Genet Genomic Med. 2024; 12(11):e70026.

PMID: 39548353 PMC: 11567815. DOI: 10.1002/mgg3.70026.


Anticipation in families with MLH1-associated Lynch syndrome.

Pandey A, Drogan C, Huo D, Postula K, Garg S, Kupfer S Cancer. 2024; 131(1):e35589.

PMID: 39435727 PMC: 11694239. DOI: 10.1002/cncr.35589.


Functional analysis of MMR gene VUS from potential Lynch syndrome patients.

Mahdouani M, Zhuri D, Sezginer Guler H, Hmida D, Sana M, Azaza M PLoS One. 2024; 19(6):e0304141.

PMID: 38843250 PMC: 11156341. DOI: 10.1371/journal.pone.0304141.


Key role of phosphorylation sites in ATPase domain and Linker region of MLH1 for DNA binding and functionality of MutLα.

Firnau M, Plotz G, Zeuzem S, Brieger A Sci Rep. 2023; 13(1):12503.

PMID: 37532794 PMC: 10397344. DOI: 10.1038/s41598-023-39750-x.


A conserved motif in the disordered linker of human MLH1 is vital for DNA mismatch repair and its function is diminished by a cancer family mutation.

Wolf K, Kosinski J, Gibson T, Wesch N, Dotsch V, Genuardi M Nucleic Acids Res. 2023; 51(12):6307-6320.

PMID: 37224528 PMC: 10325900. DOI: 10.1093/nar/gkad418.